-
Cosmo Pharmaceuticals Shares Surge After Male Hair Loss Treatment Delivers Breakthrough Phase III Results
THE WHAT? Cosmo Pharmaceuticals’ share price jumped 24% after the company reported statistically significant outcomes from two late-stage trials of its experimental male hair loss treatment. THE DETAILS The Switzerland-listed company announced that its clascoterone cream achieved major efficacy milestones in both Phase III studies. In one trial, patients recorded a 539% relative improvement…